Literature DB >> 22486525

The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop.

Morris A Blajchman1, Jeffrey L Carson, John W Eikelboom, Nancy M Heddle, Jacques Lacroix, Michael S Lauer, Richard Platt, Barbara Tilley, Darrell Triulzi, Andrew J Vickers, Salim Yusuf, Simone Glynn, Traci Heath Mondoro, Elizabeth Wagner.   

Abstract

Comparative effectiveness research (CER) is the study of existing treatments or ways to deliver health care to determine what intervention works best under specific circumstances. CER evaluates evidence from existing studies or generates new evidence, in different populations and under specific conditions in which the treatments are actually used. CER does not embrace one research design over another but compares treatments and variations in practice using methods that are most likely to yield widely generalizable results that are directly relevant to clinical practice. Treatments used in transfusion medicine (TM) are among the most widely used in clinical practice, but are among the least well studied. High-quality evidence is lacking for most transfusion practices, with research efforts hampered by regulatory restrictions and ethical barriers. To begin addressing these issues, the National Heart, Lung, and Blood Institute convened a workshop in June 2011 to address the potential role of CER in the generation of high-quality evidence for TM decision making. Workshop goals were to: 1) evaluate the current landscape of clinical research, 2) review the potential application of CER methods to clinical research, 3) assess potential barriers to the use of CER methodology, 4) determine whether pilot or vanguard studies can be used to facilitate planning of future CER research, and 5) consider the need for and delivery of training in CER methods for researchers.
© 2012 American Association of Blood Banks.

Mesh:

Year:  2012        PMID: 22486525     DOI: 10.1111/j.1537-2995.2012.03640.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Enrollment of racially/ethnically diverse participants in traumatic brain injury trials: effect of availability of exception from informed consent.

Authors:  Jose-Miguel Yamal; Claudia S Robertson; M Laura Rubin; Julia S Benoit; H Julia Hannay; Barbara C Tilley
Journal:  Clin Trials       Date:  2014-04       Impact factor: 2.486

2.  2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine.

Authors:  Pablo Cure; Melania Bembea; Stella Chou; Allan Doctor; Anne Eder; Jeanne Hendrickson; Cassandra D Josephson; Alan E Mast; William Savage; Martha Sola-Visner; Philip Spinella; Simon Stanworth; Marie Steiner; Traci Mondoro; Shimian Zou; Catherine Levy; Myron Waclawiw; Nahed El Kassar; Simone Glynn; Naomi L C Luban
Journal:  Transfusion       Date:  2017-03-28       Impact factor: 3.157

3.  Clinical trials in crisis: Four simple methodologic fixes.

Authors:  Andrew J Vickers
Journal:  Clin Trials       Date:  2014-10-01       Impact factor: 2.486

Review 4.  Does prolonged storage of red blood cells cause harm?

Authors:  Willy A Flegel; Charles Natanson; Harvey G Klein
Journal:  Br J Haematol       Date:  2014-01-25       Impact factor: 6.998

5.  Transfusion of recently donated (fresh) red blood cells (RBCs) does not improve survival in comparison with current practice, while safety of the oldest stored units is yet to be established: a meta-analysis.

Authors:  K E Remy; J Sun; D Wang; J Welsh; S B Solomon; H G Klein; C Natanson; I Cortés-Puch
Journal:  Vox Sang       Date:  2016-02-05       Impact factor: 2.144

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.